STING Activators as Therapy for Cancer
STING 激活剂治疗癌症
基本信息
- 批准号:10709468
- 负责人:
- 金额:$ 99.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-17 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAcute T Cell LeukemiaAdjuvantAdultAdult Acute Myeloblastic LeukemiaAdult T-Cell Leukemia/LymphomaAgonistAntigen-Presenting CellsAntitumor ResponseApoptoticAutoimmunityAutologousAutologous Tumor CellBacteriaBarberingBiologicalBiotechnologyBloodCAR T cell therapyCD8B1 geneCell DeathCell LineageCell NucleusCell divisionCellsCellular immunotherapyClinicClinicalClinical DataClinical TrialsCollaborationsCommunicable DiseasesCross PresentationCyclic GMPCytosolCytotoxic T-LymphocytesDNADNA DamageDataDendritic CellsDeoxyribonucleasesDevelopmentDinucleoside PhosphatesDiseaseEmbryoEventExodeoxyribonuclease IIIFDA approvedFutureGenerationsHematologic NeoplasmsHost DefenseHumanHuman T-lymphotropic virus 1ImmuneImmune checkpoint inhibitorImmune signalingImmune systemImmunologicsImmunooncologyImmunotherapeutic agentIn VitroInfectionInflammationInfusion proceduresInterferon Type IInvadedLaboratoriesLengthLettersLeukemic CellLymphoblastic LeukemiaLymphoid CellMacrophageMalignant - descriptorMalignant NeoplasmsModelingMusMyeloid CellsMyeloid LeukemiaNormal CellNucleic AcidsNucleotidesParticipantPatientsPeriodicityPhagocytesPhagocytosisPhase I Clinical TrialsPlayProcessProductionPropertyProteinsRefractoryRelapseResearchResearch PersonnelResistanceRoleSafetySignal PathwaySignal TransductionStimulator of Interferon GenesT-Cell LeukemiaT-LymphocyteTechniquesTechnologyTestingTherapeuticTherapeutic TrialsThree Prime Repair Exonuclease 1Toxic effectTumor AntigensTumor BurdenTumor ImmunityUniversitiesWorkadult acute myeloid leukemia cellanimal dataanti-canceranti-tumor immune responseantigen-specific T cellscancer cellcancer therapyconventional therapycytokinedefense responseds-DNAfightingimmunogenicin vivoleukemiamicrobialmouse modelneoplastic cellnovelnovel strategiespersonalized approachphase I trialpilot trialpre-clinicalpreventsensortumorultraviolet irradiation
项目摘要
PROJECT SUMMARY
The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune
system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer
cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This
signaling process is largely governed by STING (stimulator of interferon genes), a cellular protein discovered by
the laboratory of Dr. Glen N. Barber that plays an essential role in host defense against infectious disease and
cancer. Activation of STING triggers cytokine production and facilitates tumor antigen cross-presentation.
Indeed, considerable effort is now underway in the biotech arena to discover techniques to augment STING
activity with the objective of invigorating the generation of anti-tumor cytotoxic T cells. Along with check-point
inhibitors and CAR-T cell therapy, the plausible utilization of STING agonists affords a new, complementary
immunotherapeutic strategy to treat malignant disease.
Here, STINGINN, LLC (“STINGINN”), in collaboration with the University of Miami, proposes to perform an FDA
approved investigator sponsored small Phase I clinical trial for patients suffering from highly aggressive
leukemias, specifically relapsed/refractory acute myeloid leukemia (AML) and adult lymphocytic leukemia (ALL)
focusing on HTLV-1 associated adult T cell lymphocytic leukemia (ATLL). Our strategy involves reinfusing
autologous tumor cells loaded with STING-dependent adjuvants (STAVs) into patients to stimulate APCs in vivo
and thus anti-tumor CTL’s. Our pre-clinical data indicates that STAV loaded cells are highly immunogenic, potent
activators of APC’s. We have already submitted an IND FDA application based on this work and have assembled
an appropriate team to carry out the proposed trial. Our proposal is also applicable to a variety of cancers, not
just leukemia, providing the opportunity to initiate a number of alternate cancer therapeutic trials in the future.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEONGHYUN AHN其他文献
JEONGHYUN AHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEONGHYUN AHN', 18)}}的其他基金
Human specific STING agonists for the treatment of cancer
用于治疗癌症的人类特异性 STING 激动剂
- 批准号:
10759593 - 财政年份:2023
- 资助金额:
$ 99.39万 - 项目类别:
相似海外基金
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
6641447 - 财政年份:2002
- 资助金额:
$ 99.39万 - 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
6468895 - 财政年份:2001
- 资助金额:
$ 99.39万 - 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
6334989 - 财政年份:2000
- 资助金额:
$ 99.39万 - 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
6103535 - 财政年份:1999
- 资助金额:
$ 99.39万 - 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
6269935 - 财政年份:1998
- 资助金额:
$ 99.39万 - 项目类别:
ROLE OF THE TCL-5 GENE IN ACUTE T CELL LEUKEMIA AND MELANOMA
TCL-5 基因在急性 T 细胞白血病和黑色素瘤中的作用
- 批准号:
5207623 - 财政年份:
- 资助金额:
$ 99.39万 - 项目类别: